Literature DB >> 22793946

An integrated approach to the medical treatment of chronic obstructive pulmonary disease.

Sharon R Rosenberg1, Ravi Kalhan.   

Abstract

COPD is a treatable condition for which careful and objective evaluation of patients’ lung function, symptoms, exercise capacity, and exacerbation history on an ongoing basis is essential so that treatments may be individualized as much as possible. Although the comparative effectiveness of drug classes has not yet been tested completely in COPD, virtually all inhaled COPD therapies improve lung function, quality of life, and reduce COPD exacerbations, which fulfills the major goals of care. Pulmonary rehabilitation is safe, effective, and a crucial component of COPD therapy. Newer therapies have been developed with the specific purpose of reducing COPD exacerbations and should be prescribed to individuals who have evidence of recurrent exacerbations despite maximal inhaled maintenance medications.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22793946     DOI: 10.1016/j.mcna.2012.05.002

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  4 in total

1.  Chronic Bronchitis in Chronic Obstructive Pulmonary Disease. Magnifying Why Smoking Cessation Still Matters Most.

Authors:  Sharon R Rosenberg; Ravi Kalhan
Journal:  Ann Am Thorac Soc       Date:  2016-07

2.  Two different dosages of nebulized steroid versus parenteral steroid in the management of COPD exacerbations: a randomized control trial.

Authors:  Elif Yilmazel Ucar; Omer Araz; Mehmet Meral; Esin Sonkaya; Leyla Saglam; Hasan Kaynar; Ali Metin Gorguner; Metin Akgun
Journal:  Med Sci Monit       Date:  2014-03-28

3.  Optimization of Nebulized Budesonide in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease.

Authors:  Rui Zhang; Jiechen Zhu; Yanan Liu; Yuanqin Li; Wenjing Liu; Maowei Zhang; Bi Chen; Shuyang Zhu
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-02-26

4.  Characteristics, disease burden and costs of COPD patients in the two years following initiation of long-acting bronchodilators in UK primary care.

Authors:  Yogesh Suresh Punekar; Sarah H Landis; Keele Wurst; Hoa Le
Journal:  Respir Res       Date:  2015-11-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.